HCV Settlement Agreement Claim No. 1300143
- Citation
- 2004 BCSC 697
- Status
- Judgment
- Jurisdiction
- Canada
- Court
- Supreme Court of British Columbia
- Decision
- 25 May 2004
- Posture
- HCV 1986 1990 Transfused Settlement Agreement Claim / Application to Oppose Confirmation of Referee's Decision
- Language
- English
More details
- Court
- Supreme Court of British Columbia
- Decision
- 25 May 2004
- Posture
- HCV 1986 1990 Transfused Settlement Agreement Claim / Application to Oppose Confirmation of Referee's Decision
- Language
- English
On this page
Professional case brief
Research organized from the available case record
01
Holding and result
Article 3.04(2) cannot be construed to override the mandatory rejection required by Article 3.04(1) where the traceback identifies a pre‑class period donor as HCV antibody positive; the traceback was properly conducted under the court‑approved protocol and the court must apply the Settlement Agreement, therefore the Claimant's application is dismissed.
Court disposition
Application to oppose confirmation of the Referee's decision dismissed; Referee's decision confirmed.
Orders
- Dismissal of the Claimant's application to oppose confirmation of the Referee's decision
- Referee's decision upholding the Administrator's rejection of Claim No. 1300143 is confirmed
02
Material facts
Parties
Claimant (executor of estate of deceased spouse)
Claimant Counsel: Self-RepresentedBritish Columbia Fund (Administrator)
Respondent Counsel: William A. FergusonAmounts and remedies
- Units Transfused 1982 Total: 11
- Units Transfused 1985: 4
- Units Transfused 1988: 6
- Decedent Year of Death: 1,999
03
Procedural history
Posture
HCV 1986 1990 Transfused Settlement Agreement Claim / Application to Oppose Confirmation of Referee's Decision
04
Questions and positions
Legal issues
- 01
Whether a positive traceback identifying a pre-class period donor mandates rejection under Article 3.04(1)
- 02
Whether Article 3.04(2) permits proving infection by a class period transfusion despite a positive pre-class traceback
- 03
Whether the court may depart from the Settlement Agreement terms if application produces an inequitable result
Party arguments
- Applicant
- The Claimant argued that Article 3.04(2) permits proof of infection by a transfusion in the class period notwithstanding traceback results and that it is unfair to determine a donor's 1982 status by a test conducted in 2000; the mandatory application of Article 3.04(1) may inappropriately deny a valid claim.
- Respondent
- The Administrator argued that Article 3.04(1) mandates rejection when the traceback identifies a HCV antibody positive pre-class donor, that the traceback protocol was properly followed and court‑approved, and that Article 3.04(2) applies only to permit proof despite negative traceback results and cannot overturn a positive pre-class traceback; the court must apply the settlement terms.
05
Court’s reasoning
Legal principles
- 01
Transfused HCV Settlement Agreement / Plan
Settlement agreement terms and the court‑approved Transfused HCV Plan are binding on the court and parties; the court cannot depart from those terms.
- 02
Transfused HCV Plan Article 3.04(1)
Article 3.04(1) requires rejection of a claim if the traceback identifies a pre-class period donor who tests HCV antibody positive.
- 03
Transfused HCV Plan Article 3.04(2)
Article 3.04(2) allows a primarily‑infected person to prove infection by a class period transfusion in certain circumstances but is directed at negative traceback results and does not provide an exception to a mandatory rejection for a positive pre-class donor.
- 04
Court‑approved traceback protocol accompanying Settlement Agreement
Traceback procedures conducted in accordance with the court‑approved protocol are entitled to deference in determining donor status for Plan purposes.
06
Ratio, limits and disposition
Ratio decidendi
Article 3.04(2) cannot be construed to override the mandatory rejection required by Article 3.04(1) where the traceback identifies a pre‑class period donor as HCV antibody positive; the traceback was properly conducted under the court‑approved protocol and the court must apply the Settlement Agreement, therefore the Claimant's application is dismissed.
Obiter and limits
- The parties agreed that current HCV antibody positivity would be treated as indicating past positivity for Plan purposes; that assumption may work unfairly in individual cases.
- The court's inability to depart from the Settlement Agreement means inequitable results cannot be remedied by the court in this context.
Court disposition
Application to oppose confirmation of the Referee's decision dismissed; Referee's decision confirmed.
- Dismissal of the Claimant's application to oppose confirmation of the Referee's decision
- Referee's decision upholding the Administrator's rejection of Claim No. 1300143 is confirmed
Source and reliance status
Supreme Court of British Columbia · 25 May 2004
This page organises the available record for research. Confirm quotations, current status, and subsequent treatment against the official source before relying on the case.
Judgment reading view
Judgment text
The complete available source text.
Supreme Court of British Columbia
Judgment· 25 May 2004
2004 BCSC 697 HCV Settlement Agreement Claim No. 1300143
IN THE SUPREME COURT OF BRITISH COLUMBIA Citation: HCV Settlement Agreement Claim No. 1300143, 2004 BCSC 697 Date: 20040525 Docket: C965349 Registry: Vancouver IN THE MATTER OF THE HCV 1986-1990
TRANSFUSED SETTLEMENT AGREEMENT RE: CLAIM NO. 1300143 Before: The Honourable Mr. Justice Pitfield Reasons for Judgment Counsel for the Claimant: Self-Represented Counsel for the British Columbia Fund: William A. Ferguson Submissions Received from Fund Counsel: July 11, 2003 Submissions Received from Claimant None Vancouver, B.C. [1] The Claimant is the executor of the estate of his deceased spouse who died October 5, 1999. She had suffered from Hepatitis C. The Claimant submitted a claim on behalf of the estate under the 1986-1990 Transfused HCV Settlement Agreement in his capacity as personal representative of a primarily-infected person. The Administrator rejected the claim because the traceback procedure indicated that a donor of blood with which the deceased had been transfused before the commencement of the class period which extended from January 1, 1986 to July 1, 1990, had tested positive for the HCV antibody so that infection could not be attributed solely to a transfusion within the class period. [2] The Claimant appealed to a Referee who upheld the Administrator's decision. As permitted by the provisions of the Transfused HCV Plan, the Claimant applied to oppose confirmation of the Referee's decision. [3] The delay in providing this decision in response to the Claimant's application results from the fact that the documentation pertaining to the application was
inadvertently misplaced in the court. The oversight was not discovered until May 2004 in response to an inquiry from Fund Counsel. [4] The material facts for purposes of this application are the following. The deceased was transfused with ten units of blood in January 1982, and one unit of blood in March 1982 at a British Columbia hospital. One of the donors of the blood transfused in 1982 tested positive for the HCV antibody on December 4, 2000. [5] The deceased was transfused with four units of blood in January 1985 and six units of blood in March 1988 at another British Columbia hospital. One of the donors of the blood transfused in 1988 and therefore within the class period tested positive for the HCV antibody. [6] The complication in this case arises because of the identification of a HCV antibody positive donor before and during the class period. [7] The Administrator justified the rejection of the claim by reference to Article 3.04(1) of the Transfused HCV Plan. That Article compels rejection if the traceback procedure endorsed by the court as part of the settlement process identifies a HCV antibody positive pre-class period donor. [8] The Claimant relies on Article 3.04(2) of the Plan which permits a primarily-infected person to prove infection, for the first time, by a transfusion in the class period notwithstanding the result of the traceback procedure that identified
a pre-class period donor as HCV antibody positive. The Claimant is concerned about the fact that the status of a blood donor in 1982 is being determined by reference to a test of that donor conducted some eighteen years later. The concern is understandable. Simply stated, it is impossible to know whether the 1982 donor who tested positive in 2000 was, in fact, HCV antibody positive in 1982, or became so at a later date. The blood of the donor in question was transfused as whole blood. No components of the blood were supplied to others. The lookback process cannot be used to track the history of other recipients of that donor's blood or blood products. Because of the mandatory requirement in Article 3.04(1) and the inability to prove an exception under Article 3.04(2), the Transfused HCV Plan may inappropriately operate to the Claimant's detriment. [9] The settlement concluded with the defendants was designed and intended to operate for the benefit of persons infected in the class period for the first time. It was not intended to compensate those infected outside the class period. The settlement resulted from extensive negotiations on behalf of the parties to the litigation. Those who were infected by the Hepatitis C virus were ably represented by counsel in that process. The parties settled upon the criteria by which claims were to be established. The court has no discretion to
depart from the Settlement Agreement even in circumstances where the result flowing from the application of its terms may appear to be inequitable. The court is governed by the terms of the Settlement Agreement as is every member of the Class and every party to the Agreement. [10] There is nothing to indicate that the traceback procedure followed by Canadian Blood Services in this case was improperly pursued. The 1982 donor was tested in the year 2000 and found to be positive in the manner contemplated by the traceback procedure protocol approved by the court in conjunction with the Settlement Agreement. The assumption that a person currently HCV antibody positive would be regarded as HCV antibody positive at the time of donating blood was agreed to by the parties at the time the Transfused HCV Plan was settled. The assumption may work to the detriment of some, as in this case, just as it may work to the advantage of others should they have received a transfusion of blood donated in the class period by an individual who was not infected at the time of donation but who became infected after the close of the period and before traceback. [11] While the Referee concluded that Article 3.04(2) might have application in the circumstances, it is my opinion that it cannot. The exception in Article 3.04(2) is directed at permitting a Claimant to prove infection by means of a blood transfusion notwithstanding negative traceback results. It cannot be construed to provide an exception to the mandatory denial of a claim in the event of a positive traceback in respect of a pre-class period donor. [12] The Claimant's application to oppose confirmation of the Referee's decision must be dismissed. "I.H. Pitfield, J." The Honourable Mr. Justice I.H. Pitfield
Case-aware research
Ask AI about this case
The judgment and available research above are public. New questions open in a separate private conversation grounded in this case.